The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment

Mengmeng Lin; Weiping Xiong; Shiyuan Wang; Yingying Li; Chunying Hou; Chunyu Li; Guohui Li

doi:10.3389/fcvm.2021.821663

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment

Front Cardiovasc Med. 2022 Jan 12:8:821663. doi: 10.3389/fcvm.2021.821663. eCollection 2021.

Authors

Mengmeng Lin¹, Weiping Xiong², Shiyuan Wang¹, Yingying Li¹, Chunying Hou¹, Chunyu Li¹, Guohui Li¹

Affiliations

¹ National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Department of Cardiology, Shanghai Putuo District Liqun Hospital, Shanghai, China.

Abstract

In recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal antibody against HER-2. The most significant adverse effect of trastuzumab is cardiotoxicity, which has become an important factor in limiting the safe use of the drug. Unfortunately, the mechanism causing this cardiotoxicity is still not completely understood, and the use of preventive interventions remains controversial. This article focuses on trastuzumab-induced cardiotoxicity, reviewing the clinical application, potential cardiotoxicity, mechanism and discussing the potential interventions through summarizing related researches over the past tens of years.

Keywords: adverse reaction; breast cancer; cardiotoxicity; rational drug use; trastuzumab.

Publication types

Review